BNP Paribas Financial Markets’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$387 Hold
352
﹤0.01% 5704
2026
Q1
$612 Hold
352
﹤0.01% 5521
2025
Q4
$612 Sell
352
-10,634
-97% -$23.4K ﹤0.01% 5461
2025
Q3
$25.7K Buy
10,986
+1,123
+11% +$2.15K ﹤0.01% 4845
2025
Q2
$20.1K Buy
9,863
+7,632
+342% +$14.6K ﹤0.01% 4605
2025
Q1
$3.64K Sell
2,231
-1,080
-33% -$2.17K ﹤0.01% 4902
2024
Q4
$6.06K Sell
3,311
-2,370
-42% -$10.5K ﹤0.01% 4905
2024
Q3
$32.8K Buy
5,681
+3,630
+177% +$29.9K ﹤0.01% 3691
2024
Q2
$16.6K Buy
2,051
+1,745
+570% +$18.4K ﹤0.01% 3661
2024
Q1
$4.25K Sell
306
-194
-39% -$1.68K ﹤0.01% 3753
2023
Q4
$3.06K Sell
500
-434
-46% -$2.14K ﹤0.01% 3788
2023
Q3
$4.36K Sell
934
-13,916
-94% -$76.9K ﹤0.01% 3672
2023
Q2
$79.6K Sell
14,850
-59,726
-80% -$481K ﹤0.01% 3334
2023
Q1
$734K Buy
74,576
+32,633
+78% +$556K ﹤0.01% 2510
2022
Q4
$785K Sell
41,943
-8,874
-17% -$201K ﹤0.01% 2305
2022
Q3
$1.05M Buy
50,817
+46,204
+1,002% +$1.18M ﹤0.01% 2451
2022
Q2
$95.8K Buy
4,613
+2,740
+146% +$77.2K ﹤0.01% 3368
2022
Q1
$80.7K Sell
1,873
-4,744
-72% -$214K ﹤0.01% 3424
2021
Q4
$396K Buy
6,617
+2,240
+51% +$179K ﹤0.01% 3117
2021
Q3
$376K Buy
4,377
+2,303
+111% +$231K ﹤0.01% 2857
2021
Q2
$231K Buy
2,074
+159
+8% +$15.3K ﹤0.01% 2835
2021
Q1
$213K Sell
1,915
-2,894
-60% -$381K ﹤0.01% 3015
2020
Q4
$511K Sell
4,809
-16,197
-77% -$2.16M ﹤0.01% 2449
2020
Q3
$2.92M Buy
21,006
+19,556
+1,349% +$4.08M ﹤0.01% 1328
2020
Q2
$469K Sell
1,450
-954
-40% -$153K ﹤0.01% 2126
2020
Q1
$215K Buy
2,404
+1,508
+168% +$93K ﹤0.01% 2817
2019
Q4
$35.5K Sell
896
-279
-24% -$8.4K ﹤0.01% 3822
2019
Q3
$28.9K Buy
1,175
+373
+47% +$11.3K ﹤0.01% 3772
2019
Q2
$28.3K Sell
802
-716
-47% -$28.4K ﹤0.01% 3758
2019
Q1
$67.9K Buy
1,518
+1,515
+50,500% +$76.4K ﹤0.01% 3345
2018
Q4
$124 Sell
3
-252
-99% -$15.3K ﹤0.01% 4159
2018
Q3
$17K Hold
255
﹤0.01% 3483
2018
Q2
$12K Sell
255
-1,235
-83% -$68.1K ﹤0.01% 3705
2018
Q1
$84.2K Buy
1,490
+29
+2% +$1.57K ﹤0.01% 3281
2017
Q4
$72.4K Buy
1,461
+879
+151% +$54.5K ﹤0.01% 3470
2017
Q3
$44.3K Sell
582
-44
-7% -$3.27K ﹤0.01% 3206
2017
Q2
$58.9K Buy
626
+588
+1,547% +$50.3K ﹤0.01% 3105
2017
Q1
$3.01K Sell
38
-60
-61% -$4.78K ﹤0.01% 3428
2016
Q4
$8.18K Sell
98
-284
-74% -$25.7K ﹤0.01% 3541
2016
Q3
$42.7K Buy
382
+167
+78% +$18.5K ﹤0.01% 2500
2016
Q2
$23.8K Buy
+215
New +$26.1K ﹤0.01% 2518
2016
Q1
Sell
-1,313
Closed -$106K 2866
2015
Q4
$106K Buy
1,313
+76
+6% +$6.05K ﹤0.01% 2294
2015
Q3
$85.8K Buy
1,237
+739
+148% +$64.4K ﹤0.01% 2487
2015
Q2
$48.7K Buy
498
+379
+318% +$40.5K ﹤0.01% 2509
2015
Q1
$11.7K Buy
+119
New +$11.5K ﹤0.01% 2668
2014
Q4
Sell
-297
Closed -$35.2K 2573
2014
Q3
$35.2K Buy
+297
New +$37K ﹤0.01% 2808

Other funds holding INO

BNP Paribas Financial Markets's INO Position: Q2 2026 in Review

BNP Paribas Financial Markets held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 352 shares worth $387. The position accounts for ﹤0.01% of the portfolio, ranked #5704.

BNP Paribas Financial Markets first reported a position in INO in Q3 2014 and has held it in 46 quarters since. The position peaked at $2.92M in Q3 2020. 94 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • BNP Paribas Financial Markets held 352 shares of Inovio Pharmaceuticals worth $387 as of Q2 2026.
  • BNP Paribas Financial Markets left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5704 holding.
  • BNP Paribas Financial Markets first reported a position in Inovio Pharmaceuticals in Q3 2014 and has held it in 46 quarters since.
  • BNP Paribas Financial Markets's Inovio Pharmaceuticals position peaked at $2.92M in Q3 2020.
  • 94 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.